Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2025 | June 05, 2025 |
| PFIZER INCPFE · Entity 2863 | Director | April 23, 2015 | April 24, 2015 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 03, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Denali Therapeutics Inc.
Report date June 03, 2025 · Filed June 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,886,576 |
Reported balance
After 2025-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-03 · Grant · Acquired 6,037 · Balance 1,886,576 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,037 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.93 · Expires 2035-06-03 | Direct | 18,111 |
Reported balance
After 2025-06-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-06-03 · Grant · Acquired 18,111 · Balance 18,111 F6: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 1 | 78,848 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 78,848 F3: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 2 | 79,173 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 79,173 F4: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee. |
| Common StockSEC Table I · non-derivative | IndirectThe Tessier-Lavigne/Hynes Irrevocable Trust 3 | 78,848 |
Reported balance
Holding disclosure · report date 2025-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 78,848 F5: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,037 unvested RSUs.
F3: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee.
F4: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee.
F5: The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee.
F6: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
PFIZER INC
Report date April 23, 2015 · Filed April 24, 2015
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security | Direct | 29,099.964 |
Reported balance
After 2015-04-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2015-04-23 · Grant · Acquired 4,595.588 · Balance 29,099.964 F1: Each unit represents one phantom share of common stock. F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each unit represents one phantom share of common stock.
F2: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
F3: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
REGENERON PHARMACEUTICALS, INC.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,434 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 165 · Balance 2,434 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $725.89 · Expires 2033-01-03 | Direct | 1,929 |
Reported balance
After 2023-01-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-03 · Grant · Acquired 1,929 · Balance 1,929 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2019 Filed Jan 4, 2019 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 323 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-19-000004 · edgardoc.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,510 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 22:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 27,830 | $0.00 Strike: $18.92 | $0.00 |
DisclosureSEC source: 0001209191-18-038158 · doc4.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,830 Underlying: Common Stock · 27,830 shares Expires 2028-06-12 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of the one year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, in each case, provided that the Reporting Person continues to serve as a non-employee director through the applicable vesting date. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:13 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,439 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001708138-18-000003 · edgardoc.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,439 Underlying: Common Stock · 7,439 shares Expires 2028-01-02 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionSeries A-1 Preferred Stock · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065250 · doc4.xml · derivative · entry 2 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| December 12, 2017 Filed Dec 12, 2017 22:45 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | ConversionCommon Stock | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-065250 · doc4.xml · nonDerivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,139,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 23:00 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 47,165 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-17-064812 · doc4.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,165 Underlying: Common Stock · 47,165 shares Expires 2027-12-06 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,830 | $0.00 Strike: $376.69 | $0.00 |
DisclosureSEC source: 0001237899-17-000009 · edgardoc.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,830 Underlying: Common Stock · 7,830 shares Expires 2027-01-03 F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 23, 2015 Filed Apr 24, 2015 18:00 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 4,595.588 | $35.36 | $162,499.99 |
DisclosureSEC source: 0001225208-15-010356 · doc4.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,099.964 Underlying: Common Stock · 4,595.588 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 24, 2014 Filed Apr 28, 2014 17:34 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 5,291.436 | $30.71 | $162,500.00 |
DisclosureSEC source: 0001225208-14-011190 · doc4.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,670.869 Underlying: Common Stock · 5,291.436 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 25, 2013 Filed Apr 26, 2013 20:39 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 4,543.952 | $30.26 | $137,499.99 |
DisclosureSEC source: 0001225208-13-010464 · doc4.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,793.652 Underlying: Common Stock · 4,543.952 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| April 26, 2012 Filed Apr 27, 2012 21:41 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 5,962.7 | $23.06 | $137,499.86 |
DisclosureSEC source: 0001225208-12-010384 · doc4.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,776.2 Underlying: Common Stock · 5,962.7 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| December 12, 2011 Filed Dec 13, 2011 21:55 UTC | PFIZER INC PFE · Entity 2863 | GrantPhantom Stock Units · Derivative | 6,744 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-026254 · doc4.xml · derivative · entry 1 Tessier-Lavigne Marc · CIK 0001437435 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,744 Underlying: Common Stock · 6,744 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · shares: Granted pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors. F3 · derivative.exercise_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. F3 · derivative.expiration_date: These units represent deferred director's compensation that are settled in cash or common stock at the director's election, following the reporting person's retirement from the Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.